| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥377.5B | ¥373.8B | +1.0% |
| Operating Income | ¥17.6B | ¥23.5B | -25.1% |
| Ordinary Income | ¥19.0B | ¥24.3B | -21.8% |
| Net Income | ¥12.7B | ¥16.7B | -24.2% |
| ROE | 2.9% | 3.9% | - |
FY2025 Q3 results: Revenue 377.5B yen (YoY +1.0%), Operating Income 17.6B yen (YoY -25.1%), Ordinary Income 19.0B yen (YoY -21.8%), Net Income 12.7B yen (YoY -24.2%). While top-line revenue remained stable with marginal growth, bottom-line profitability contracted significantly. Gross profit margin held at 29.9%, but elevated selling, general and administrative expenses combined with non-recurring charges including impairment loss of 530M yen and disposal loss of 380M yen compressed operating margin to 4.7%. The company maintains a conservative balance sheet with total assets of 680.9B yen and equity of 437.6B yen, representing an equity ratio of 64.3%. Interest-bearing debt stands at a modest 20.0B yen. Current ratio of 217.5% and quick ratio of 186.9% indicate solid short-term liquidity, though working capital efficiency metrics show room for improvement with extended receivables and inventory turnover periods.
Revenue increased 1.0% YoY to 377.5B yen, driven by relatively stable demand across core product categories. Domestic sales reached 339.4B yen with the Consumer Marketing Division (Healthcare, EC, and Stationery fields) contributing 191.4B yen, Medical Materials field generating 44.3B yen, and Industrial Products field adding 103.7B yen. Overseas sales through the Global field increased 3.2% to 38.1B yen. The marginal revenue growth reflects steady baseline demand maintenance rather than expansion, with no single segment driving significant volume gains. On the profit side, gross profit decreased to 113.0B yen despite stable gross margin, as cost of sales rose in line with revenue. The primary profit compression factor was SG&A expenses reaching 95.4B yen, which grew faster than revenue and exceeded prior year levels. This SG&A burden, combined with non-recurring charges totaling 910M yen (impairment 530M yen, disposal loss 380M yen), resulted in operating income declining 25.1% to 17.6B yen. Operating margin contracted from 6.3% to 4.7%. Non-operating income provided modest relief with net non-operating gains of approximately 1.4B yen, primarily from equity method investment gains and financial income including some foreign exchange gains, bringing ordinary income to 19.0B yen (down 21.8%). After-tax income of 12.7B yen reflects an effective tax rate of approximately 30.4%. The performance pattern is revenue stable/profit down, driven by operating expense pressure and one-time charges rather than demand weakness.
The Medical segment generated revenue of 18.9B yen with operating income of 4.8B yen, representing an operating margin of 25.5%. This segment decreased operating income by 383M yen YoY (from 5.2B yen to 4.8B yen), primarily due to impairment charges on construction-in-progress assets totaling 530M yen in the prior period, though the current period shows no such charges. The Tape segment recorded revenue of 19.0B yen with operating income of 595M yen, yielding a significantly lower operating margin of 3.1%. Tape segment operating income declined 17M yen YoY (from 612M yen to 595M yen). The Medical segment represents the core high-margin business with substantially superior profitability compared to Tape, which operates at thin margins. The segment-level performance indicates that Medical maintains structural profitability advantages, while Tape faces margin pressure. Combined segment operating income totaled 5.4B yen before corporate overhead allocation of 3.6B yen (primarily unallocated general administrative expenses), resulting in consolidated operating income of 1.8B yen on a segment-adjusted basis.
[Profitability] ROE 2.9% declined from higher historical levels, reflecting the contraction in net income against stable equity base, with DuPont decomposition showing net profit margin of 3.4%, asset turnover of 0.554x, and financial leverage of 1.56x as primary components. Operating margin compressed to 4.7% from 6.3% YoY, marking a deterioration of 1.6 percentage points driven by SG&A expansion and non-recurring charges. EBIT margin stands at 4.7%, indicating limited operating profitability cushion. [Cash Quality] Cash and deposits totaled 131.6B yen, providing coverage of 2.51x against short-term debt, indicating ample liquidity buffers. Working capital metrics show extended cycles with days sales outstanding, days inventory outstanding, and cash conversion cycle all elevated, suggesting operational efficiency opportunities. [Investment Efficiency] Total asset turnover of 0.554x falls within typical manufacturing ranges but indicates moderate asset utilization intensity. Fixed asset turnover and ROIC metrics suggest capital-intensive operations with room for productivity gains. [Financial Health] Equity ratio of 64.3% substantially exceeds typical leverage levels, reflecting conservative capitalization. Current ratio of 217.5% and quick ratio of 186.9% demonstrate strong short-term solvency. Debt-to-equity ratio of 0.046x represents minimal financial leverage. Interest coverage ratio of 53.36x indicates negligible interest burden relative to operating earnings.
Cash and deposits increased 8.1B yen YoY to 131.6B yen, reflecting positive cash accumulation despite profitability pressures. The improvement in cash position occurred alongside operating profit generation, though the magnitude suggests additional factors beyond earnings retention. Working capital movements show accounts receivable increasing to 73.5B yen and inventories reaching 90.9B yen, both elevated levels that tie up operating cash. The extended receivables turnover of 71.2 days and inventory turnover of 246.4 days indicate slower cash conversion than optimal, requiring monitoring for potential liquidity drag. Accounts payable stood at 40.7B yen with turnover of 44.1 days, showing modest supplier credit utilization. The net working capital position expanded, suggesting operational cash generation was partially offset by working capital build. Cash coverage of short-term liabilities remains robust at 2.51x for short-term debt and adequate against total current liabilities, providing confidence in near-term financial flexibility. The balance sheet structure with minimal debt and substantial cash reserves offers cushion against temporary earnings volatility.
Ordinary income of 19.0B yen versus operating income of 17.6B yen indicates net non-operating contribution of approximately 1.4B yen, representing 0.4% of revenue. This modest positive contribution comprises primarily equity method investment gains and financial income including interest, dividends, and some foreign exchange gains, all of which represent relatively stable recurring sources. The non-operating income is not material relative to core operations, suggesting earnings quality is predominantly driven by operating performance rather than non-operating items. The presence of non-recurring charges totaling 910M yen (impairment loss 530M yen, disposal loss 380M yen) in the current period depressed reported earnings below normalized run-rate, though these are clearly identified as extraordinary items. Adjusting for these one-time charges would place normalized operating income closer to 18.5B yen. The gap between reported net income of 12.7B yen and operating cash generation capacity warrants assessment: while direct operating cash flow data is not disclosed, the extended working capital cycles (high DSO and DIO) suggest that accounting earnings may not fully convert to cash in the near term, indicating accruals-related earnings quality considerations. The tax burden coefficient of 0.695 reflects standard effective tax rates without unusual tax-related earnings manipulation.
Full-year guidance projects revenue of 500.0B yen, operating income of 22.0B yen, ordinary income of 23.0B yen, and net income of 14.0B yen. Through Q3 (nine months), progress rates stand at: Revenue 75.5%, Operating Income 80.0%, Ordinary Income 82.6%, Net Income 90.4%. Revenue progress aligns closely with the standard 75% benchmark for Q3, indicating on-track performance. Operating and ordinary income progress rates of 80-83% exceed the standard 75% pace, suggesting somewhat front-loaded profit recognition or conservatism in full-year guidance. Net income progress at 90.4% significantly exceeds the expected 75% pace, which may reflect timing of tax provisions or prior period adjustments. The guidance implies Q4 revenue of 122.5B yen (up from Q3 run-rate) and operating income of 4.4B yen, suggesting anticipated seasonal strength or recovery in the final quarter. The forecast assumes operating margin recovery to approximately 4.4% for the full year (from current 4.7% through nine months), which appears achievable if Q4 controls SG&A and avoids further non-recurring charges. Year-over-year guidance changes show revenue growth of 1.1%, operating income decline of 15.0%, and ordinary income decline of 14.2%, indicating management's expectation that profitability pressures will persist through year-end despite stable top-line.
Annual dividend per share is planned at 40 yen (interim dividend details not specified in disclosed data, with year-end dividend of 35 yen indicated). Based on full-year net income guidance of 14.0B yen and assuming approximately 203M shares outstanding (implied from EPS forecast of 68.77), total dividends would approximate 8.1B yen, yielding a payout ratio of approximately 57.9% against forecasted earnings. Against actual nine-month net income of 12.7B yen annualized, the current payout trajectory implies approximately 57.3% payout ratio. This level falls within sustainable ranges given the company's strong balance sheet and cash reserves of 131.6B yen, though the elevated payout relative to compressed earnings warrants attention if profitability does not recover. The dividend policy maintains continuity with prior levels, reflecting management commitment to shareholder returns despite near-term earnings pressure. No share buyback activity is disclosed in the available data. The total shareholder return ratio equals the dividend payout ratio of approximately 58% in the absence of buybacks.
First, operating margin compression risk: SG&A expenses of 95.4B yen grew faster than revenue, and if this trend persists without commensurate sales growth or cost control measures, operating margins could deteriorate further from the current 4.7% level, threatening profitability and dividend sustainability. Second, working capital efficiency risk: receivables turnover of 71.2 days and inventory turnover of 246.4 days both exceed optimal levels, indicating potential cash conversion delays that could pressure liquidity despite strong current ratios, particularly if sales slow or inventory obsolescence emerges. Third, segment margin divergence risk: the Tape segment operates at only 3.1% operating margin compared to Medical's 25.5%, meaning any adverse volume or pricing pressure in the low-margin Tape business could disproportionately impact consolidated profitability, while limited diversification outside these two segments concentrates business risk.
[Industry Position] (Reference - Proprietary Analysis) Nichiban's profitability metrics fall below manufacturing sector medians. Operating margin of 4.7% significantly trails the industry median of 8.7% (IQR: 5.1%-12.6%, n=100), placing the company in the lower quartile and indicating operational efficiency challenges relative to peers. Net profit margin of 3.4% also lags the industry median of 6.4% (IQR: 3.3%-9.3%, n=100), consistent with the operating margin underperformance. ROE of 2.9% substantially underperforms the industry median of 5.2% (IQR: 3.0%-8.3%, n=100), reflecting both lower profitability and conservative leverage. Revenue growth of 1.0% YoY aligns with the industry median of 2.8% (IQR: -1.7%-8.1%, n=100), showing stable but unexceptional top-line performance. The equity ratio of 64.3% exceeds the industry median of 63.8% (IQR: 49.4%-74.5%, n=100), confirming the company's conservative financial positioning. Asset turnover of 0.554x slightly trails the industry median of 0.58 (IQR: 0.41-0.66), suggesting comparable asset intensity. Working capital metrics show extended cycles: receivables turnover of 71.2 days compares favorably to the median of 82.87 days, but inventory turnover of 246.4 days significantly exceeds the median of 108.81 days (IQR: 49.81-154.58), highlighting inventory management as a key efficiency gap. Current ratio of 217.5% falls below the industry median of 2.83x, though still indicates strong liquidity. Overall, Nichiban demonstrates below-median profitability and operating efficiency relative to manufacturing peers, offset by above-average financial conservatism. (※ Industry: Manufacturing (100 companies), Comparison: 2025-Q3 fiscal period, Source: Proprietary analysis)
First, the company exhibits a revenue stability/profit pressure pattern where top-line resilience at 1.0% growth contrasts sharply with 25.1% operating income decline, driven primarily by SG&A expense expansion and non-recurring charges totaling 910M yen; normalized earnings power appears approximately 15-20% below current reported figures when excluding one-time items, suggesting underlying operating leverage deterioration requires structural cost management to restore margin trajectory. Second, working capital efficiency represents a significant value creation opportunity: inventory turnover of 246.4 days substantially exceeds manufacturing sector median of 108.81 days, implying roughly 130-140 days of excess inventory holding that ties up an estimated 40-50B yen in capital; optimization of this working capital could materially improve cash conversion cycles and return on invested capital without requiring revenue growth. Third, the segment profitability gap between Medical (25.5% operating margin) and Tape (3.1% margin) creates both risk concentration and portfolio optimization questions; the high-margin Medical business drives economic value while Tape operates near breakeven, suggesting strategic review of capital allocation and potential for margin improvement in the lower-performing segment could unlock shareholder value.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.